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Table S1. 35G8 analogues available from the NCI database. Compounds marked with an asterisk (*) 
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Figure S1. Docking poses of 35G8 analogues. (A) Docking poses of the 35G8 analogues docked in the 
Cys397 catalytic site of PDI along with PoseView representation showing the interactions with the 
binding site residues. (B) Heat map plot for docking of 35G8 analogues toward three binding sites of PDI. 
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Figure S2. (A) Cytotoxicity data for U87MG cells treated with Z-VAD-FMK (50 µM) or necrostatin (50 
µM) + 35G8. (B) DFO decreases the potency of 35G8. U87MG cells were subjected to 100 μM DFO at 












35G8 + ZVAD (50 μM)
35G8 + Necrostatin (50 μM)
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Table S2. Top 20 upregulated genes upon 35G8 treatment 
 
Gene Symbol Gene Name (Description)  Fold change 
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 62.28 
AKR1C1 interleukin-6 (IL-6), aldo-keto reductase 1C1 59.25 
CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 46.09 
TMEM74 transmembrane protein 74 27.77 
LOC344887 similar to hCG2041270 23.27 
TRIB3 tribbles homolog 3 (Drosophila) 23.22 
LOC388692 similar to UPF0627 protein ENSP00000358171; hypothetical LOC388692 19.60 
HMOX1 heme oxygenase (decycling) 1 19.16 
F2RL2 coagulation factor II (thrombin) receptor-like 2 17.42 
WDR74 WD repeat domain 74 17.31 
TNFSF9 tumor necrosis factor (ligand) superfamily, member 9 17.05 
TMEM107 transmembrane protein 107 15.22 
C12orf57 chromosome 12 open reading frame 57 14.33 
LOC643723 hypothetical LOC643723 13.44 
INHBA inhibin, beta A 13.14 
ARG2 arginase, type II 12.46 
IRS2 insulin receptor substrate 2 11.73 
HKDC1 hexokinase domain containing 1 11.41 
GLA galactosidase, alpha 11.26 
















Table S3. Top 20 downregulated genes upon 35G8 treatment 
 
Gene Symbol Gene Name (Description) Fold change 
TXNIP thioredoxin interacting protein -7.40 
EGR1 early growth response 1 -5.65 
HIST1H2AB histone cluster 1, H2ae; histone cluster 1, H2ab -5.08 
CSF3 colony stimulating factor 3 (granulocyte) -4.96 
HIST1H2AC histone cluster 1, H2ac -4.52 
HIST1H2BO histone cluster 1, H2bo -4.40 
HIST1H2BK histone cluster 1, H2bk -4.37 
HIST1H2BJ histone cluster 1, H2bj -4.37 
STAMBPL1 STAM binding protein-like 1 -4.35 
PRDM8 PR domain containing 8 -4.28 
HIST1H2BE  histone cluster 1, H2be -4.23 
HIST1H2AL  histone cluster 1, H2al -4.21 
MIF macrophage migration inhibitory factor (glycosylation-inhibiting factor) -4.06 
HIST1H3G  histone cluster 1, H3g -3.99 
NDP Norrie disease (pseudoglioma) -3.99 
POLR2L polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa -3.98 
ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) -3.89 
HIST1H3D histone cluster 2, H3d -3.89 
HIST1H3F histone cluster 1, H3f -3.84 


















Table S4. Top 20 Ingenuity canonical pathways correlating with 35G8 treatment identified by IPA 
 
Ingenuity Canonical Pathway p-value Molecules 




X1,KEAP1, JUND, TXN,DNAJB1,GCLM,MGST1,NQO1, H
ERPUD1,DNAJB9, TXNRD1,GSR, FOS,DNAJB11,SQSTM1,
ENC1,FTH1,EPHX1 






















Antigen Presentation Pathway 1.58E-04 CALR,PDIA3,HLA-DMA,HLA-DRA,CIITA,CANX,PSMB8 






Endoplasmic Reticulum Stress  
Pathway 4.68E-04 CALR,HSP90B1,DDIT3,XBP1,HSPA5 
Vitamin-C Transport 8.51E-04 TXN,GLRX,SLC2A3,TXNRD1 
Superpathway of Serine and  
Glycine Biosynthesis I 1.07E-03 PSAT1,PHGDH,SHMT2 
Role of Macrophages, Fibroblasts  






Glutathione Biosynthesis 3.09E-03 GCLC,GCLM 
Glutathione Redox Reactions II 3.09E-03 GSR,GLRX 
Methylglyoxal Degradation III 3.39E-03 AKR1C1/AKR1C2,AKR1B1,AKR1B10 
Mitotic Roles of Polo-Like Kinase 4.17E-03 CDC25C,HSP90B1,PLK4,CDC20,PLK2,WEE1,PLK1 
Hypoxia Signaling in the  
Cardiovascular System 4.17E-03 
VEGFA,HSP90B1,UBE2H,NQO1,MDM2,CREB5, 
UBE2D1 
p53 Signaling 4.47E-03 
PMAIP1,TP53INP1,GADD45A,MDM2,BAX,PML, 
CCND1,CDK2,SERPINE2 
p38 MAPK Signaling 4.68E-03 
HSPB3,TGFBR2,IL1A,DDIT3,DUSP10,HIST1H3C, 
IL36RN,CREB5,IL36B,HSPB1 
Cell Cycle: G2/M DNA Damage  





Table S5. Top 20 gene sets for upregulated genes from 35G8 treatment obtained by GSEA 
 
Gene set Size NES FDR q-val 
NFE2L2.V2 154 2.702 < E-06 
PODAR_RESPONSE_TO_ADAPHOSTIN_UP 115 2.665 < E-06 
GSE9988_ANTI_TREM1_AND_LPS_VS_VEHICLE_TREATED_ 
MONOCYTES_UP 127 2.664 < E-06 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_ 
BLUE_UP 113 2.629 < E-06 
BLUM_RESPONSE_TO_SALIRASIB_UP 201 2.558 < E-06 
GSE9988_ANTI_TREM1_VS_CTRL_TREATED_MONOCYTES_UP 143 2.550 < E-06 
HELLER_SILENCED_BY_METHYLATION_DN 62 2.515 < E-06 
GSE9988_ANTI_TREM1_VS_VEHICLE_TREATED_MONOCYTES_ 
UP 135 2.510 < E-06 
TIEN_INTESTINE_PROBIOTICS_24HR_DN 181 2.498 < E-06 
KRIGE_AMINO_ACID_DEPRIVATION 25 2.486 < E-06 
GHANDHI_BYSTANDER_IRRADIATION_UP 47 2.438 < E-06 
GSE9988_ANTI_TREM1_AND_LPS_VS_CTRL_TREATED_ 
MONOCYTES_UP 138 2.438 < E-06 
MTOR_UP.N4.V1_UP 121 2.433 < E-06 
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_UP 159 2.428 < E-06 
PACHER_TARGETS_OF_IGF1_AND_IGF2_UP 20 2.414 < E-06 
ONDER_CDH1_TARGETS_2_DN 109 2.354 < E-06 
GSE22886_DAY0_VS_DAY1_MONOCYTE_IN_CULTURE_DN 131 2.345 < E-06 
ONDER_CDH1_TARGETS_1_UP 65 2.344 < E-06 
GHANDHI_DIRECT_IRRADIATION_UP 59 2.343 < E-06 





Table S6. Top 20 gene sets for downregulated genes from 35G8 treatment obtained by GSEA  
 
Gene set Size NES FDR q-val 
GNF2_CENPF 59 -2.842 < E-06 
GNF2_CCNA2 66 -2.801 < E-06 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 122 -2.792 < E-06 
GNF2_CCNB2 52 -2.726 < E-06 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR 108 -2.709 < E-06 
GNF2_PCNA 66 -2.698 < E-06 
KOBAYASHI_EGFR_SIGNALING_24HR_DN 226 -2.666 < E-06 
GNF2_CDC2 59 -2.659 < E-06 
GNF2_CDC20 52 -2.640 < E-06 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR 74 -2.637 < E-06 
GNF2_SMC4L1 83 -2.613 < E-06 
CHANG_CYCLING_GENES 123 -2.595 < E-06 
GNF2_HMMR 46 -2.587 < E-06 
ISHIDA_E2F_TARGETS 45 -2.584 < E-06 
GNF2_RRM2 38 -2.572 < E-06 
GNF2_FEN1 56 -2.547 < E-06 
GNF2_MCM4 52 -2.507 < E-06 
CROONQUIST_NRAS_SIGNALING_DN 61 -2.507 < E-06 













































Figure S5. 35G8 treatment decreases the rate of transcription of several genes involved in DNA repair 
pathways including (a) blm, (b) rad51, (c) pold3, (d) rad54fbsbp, (e) pole2, (f) pole, (g) ung, (h) parp1, 










Figure S6. 35G8 treatment increases the rate of transcription of (a) hmox1, (b) irs2, and (c) slc7a11 and 




Table S7. IC50 values for 35G8 + NAC treatment in glioblastoma cancer cell lines. Four concentrations of 
NAC added to cells with 35G8. 
 
 (μM) 50IC 35G8 (mM) 50IC 
Cell Lines NAC (mM)  + NAC only 
 0 1 5 10  
U87MG 1.1 ± 0.02 1.1 1.2 0.8 10.0 
U118MG 2.0 ± 0.6 0.7 0.6 0.03 10.1 
NU04 0.8 ± 0.2 0.8 0.9 0.8 10.5 







Table S8. Chemical properties of synthesized 35G8 analogues  
Molecule MW ALogP S+Swa T_PSAb NRBOc S+BBB_Filterd 
35G8 (4a) 207.19 -1.08 5.34 82.7 0 High 
4b 269.26 0.59 0.38 82.7 1 High 
4c 283.29 0.62 0.76 82.7 2 High 
4d 299.28 0.57 0.38 91.9 2 High 
4f 314.26 0.48 0.29 128.0 2 High 
5d 315.28 0.29 5.18 104.0 2 High 
a Water solubility (mg/ml) calculated by ADMET predictor 
b Topological version of polar surface area calculated by ADMET predictor 
c Number of rotatable bonds 









Figure S7. The property histogram of the distribution of calculated values of ADMET predictor 
descriptors for compounds of the pyrimidotriazinedione class: (A) Moriguchi estimation of logP, (B) 
logarithm of water solubility, (C) molecular weight, (D) topological version of polar surface area, (E) 
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Figure S8. Redox-cycling characterstics of 35G8 do not interfere with PDI activity in the insulin 
turbidity assay. (A) Redox cycling assay measuring absorbance at 610 nm. Data are presented as mean ± 
standard deviation of three independent experiments. (B) H2O2 in insulin turbidity assay. Ability of PDI to 
reduce insulin measured in the presence of 10 μM and 100 μM H2O2, and 10 μM 35G8. ● Sodium 
phosphate buffer only.  130 μM insulin in buffer and DTT  1 μM PDI + 130 μM insulin + DTT  10 
μM 35G8 in 1 μM PDI + 130 μM insulin + DTT  10 μM H2O2 in 1 μM PDI + 130 μM insulin + DTT 







Figure S9. Venn diagram comparing genes that were upregulated more than two-fold upon erastin 
treatment compared to DMSO treatment and genes whose rate of transcription increased upon treatment 
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Overlapping genes:
SLC7A11 DDIT3
CHAC1 XBP1
TRIB3 ATF3
ASNS DDIT4
PSAT1 C9orf150
HERPUD1 CEBPG
SESN2 TUBE1
JDP2 SLC3A2
SLC7A5 GPT2
VLDLR
